Table 1.

Main characteristics of included studies.

Study	Year	Phase	TNBC patients, n	Treatments	pCR rate, %	Ref
GEICAM	2012	II	46	EC-D	30	21
			48	EC→DCb	30
Ando M et al	2014	II	91	P→CEF	17.6	22
			88	PCb→CEF	31.8
GeparSixto	2014	II	157	P+A+Beva	36.9	19
			158	P+A+Beva+Cb	53.2
Mexico	2017	II	31	P→AC	39.2	23
			30	PCis→AC	58.6
CALGB 40603	2015	II	107	P→AC	39	17
			105	P+Bev→AC	43
			111	P+Cb→AC	49
			110	P+Cb+Bev→AC	60
GeparSepto	2016	III	137	P→AC	26	13
			139	nabP→AC	48
I-SPY2	2016	II	44	P-AC	26	15
			72	P+Cb+Veli→AC	51
Zhang et al	2016	II	47	PCb	38.6	24
			44	PE	14
WSG-ADAPT-TN	2017	II	146	nabP+Cb	45.9	25
			178	nabP+Gem	28.7
BrightNess	2018	III	158	P→AC	31	18
			160	P+Cb→AC	58
			316	P+Cb+Veli→AC	53
ETNA	2018	II	110	P→AC	37.3	16
			109	nabP→AC	41.3
GeparNeuvo	2019	II	86	nabP→AC	53.4	37
			88	nabP+Durv→AC+Durv	44.2
GeparOLA	2019	II	50	P+Olap→AC	56	14
			27	P+Cb→AC	59.3
NeoTRIP	2019	III	138	nabP+Cb+Ate	43.5	27
			142	nabP+Cb	40.8
GeparOcto	2019	II	470	E→P→C	48	20
			475	PMCb	48.3
NeoStop	2019	II	48	PCb→AC	55	28
			52	DCb	52
KEYNOTE 522	2020	III	401	P+Cb+Pem→AC+Pem	64.8	26
			201	P+Cb→AC	51.2
NeoCart	2020	II	44	EC→D	38.6	30
			44	DCb	61.4
TBCRC 030*	2019	II	71	Cis	38	32
			67	P	43.3
TBCRC 031*	2020	II	60	Cis	18	29
			58	AC	26
IMpassion031	2020	III	168	nabP→AC	41	31
			165	nabP+Ate→AC+Ate	58

A, doxorubicin; Ate, atezolizumab; Bev, bevacizumab; C, cyclophosphamide; Cb, carboplatin; Cis, cisplatin; D, docetaxel; Durv, durvalumab; E, epirubicin; F, fluorouracil; Gem, gemcitabine; M, non-pegylated liposomal doxorubicin; NabP, nab-paclitaxel; Ola, olaparib; P, pacalitaxel; pCR, pathological complete response; PD-1, program death-1; PD-L1, program death ligand-1; Pem, pembrolizumab; TNBC, triple-negative breast cancer; Veli, veliparib. *These 2 trials were not included in the network meta-analysis.